Benzinga | Aug 11, 2021 04:53AM EDT

Goldman Sachs Downgrades Arcturus Therapeutics to Sell, Announces $29 Price Target

Goldman Sachs analyst Madhu Kumar downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Sell and announces $29 price target.